MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Functional and Neuroplastic Changes Following a 4-Week Non-Motorized Treadmill Training Program: A Pilot Study

    A. Boddy, C. Smith, O. Salmon, M. Mastrodicasa, A. Silva, T. Barrett (Waco, USA)

    Objective: The purpose of this study is to determine the neuroplastic effects on high-intensity gait training on gait parameters, motor disease severity, and quality of…
  • 2025 International Congress

    Efficacy of Combined Transcranial Direct Current Stimulation (tDCS) and Gait Training on Gait in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    A. Hegazi, H. Hussein, R. Mohamed (Mansoura, Egypt)

    Objective: To evaluate the effects of addition of tDCS to gait training  on gait parameters and motor function in individuals with Parkinson’s disease Background: Gait…
  • 2025 International Congress

    Increasing Physical Activity in Parkinson’s Disease Via a Remotely Deployed Gamification Intervention

    J. Morley, K. Waddell, M. Smith, S. Wood, R. Greysen (Philadelphia, USA)

    Objective: To determine feasibility and estimate effect of a remote behavioral intervention on daily steps and motor symptoms in Veterans with PD Background: Many types…
  • 2025 International Congress

    Harnessing Digital Biomarkers to Monitor Early Parkinson’s Disease Progression

    V. Shah, C. Silva-Batista, D. Engel, A. Ragothaman, P. Burgos, P. Carlson-Kuhta, F. Horak, M. Mancini (Philadelphia, USA)

    Objective: This study aimed to identify gait metrics capable of capturing disease progression in individuals with early Parkinson’s disease (PD). Background: Digital gait assessments have…
  • 2025 International Congress

    Effects of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy on Motor Complications in Parkinson’s Disease

    E. Tharp, J. Martinez-Lemus, C. Onuigbo, T. Thomas, C. Green, J. Suescun, T. Le, E. Rodarte, R. Ritter Iii, T. Ellmore, M. Schiess (New York, USA)

    Objective: To evaluate the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) treatment on motor complications in Parkinson’s disease (PD). Background: Motor…
  • 2025 International Congress

    Lived Experiences in early clinical PD: Developing a Framework of a Novel Patient-reported Outcome (PRO) Fit-for-purpose for Disease Modification Therapeutic Trials

    T. Mestre, J. Ding, N. Lapelle, G. Stebbins (Chicago, USA)

    Objective: To characterize the lived experience of individuals at a prodromal stage of PD or with a recent clinical diagnosis. Background: There is no validated…
  • 2025 International Congress

    Findings of motoric and neuro psychological outcome using high frequency stimulations in Parkinsons with STN-DBS

    A. Dabbeta, V. Rama Raju (Hyderabad, India)

    Objective: For testing the likelihood of decreasing psychiatric dyskinesias of STN-DBS, conducting experimentally and through experimental studies we explore the properties of in what best…
  • 2025 International Congress

    The effect of trial numbers on prism adaptation in Parkinson’s disease

    K. Taneda, T. Shimizu, N. Tokuda, S. Moriyasu, T. Nakamura, T. Murakami, Y. Ugawa, R. Hanajima (Yonago, Japan)

    Objective: We aimed to investigate the relationship between exposure trials and the acquisition of prism adaptation or the after-effect (AE) in patients with Parkinson's disease…
  • 2025 International Congress

    Investigating the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In Vitro Models

    SEO. Seo, FAZ. Dustov (Tashkent, Uzbekistan)

    Objective: This study aims to evaluate the neuroprotective potential of various mushroom extracts in in vitro models of PD. Background: Parkinson’s disease (PD) is a…
  • 2025 International Congress

    Cognitive Effects of Istradefylline in Parkinson’s Disease: A 26-Week Open-Label Pilot Study

    M. Barrett, R. Heo, N. Mukhopadhyay (Richmond, USA)

    Objective: The objective of this study was to collect preliminary evidence whether istradefylline may improve cognition in Parkinson’s disease (PD) patients with cognitive impairment. Background:…
  • « Previous Page
  • 1
  • …
  • 117
  • 118
  • 119
  • 120
  • 121
  • …
  • 181
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley